European Investment Bank

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2023

Retrieved on: 
Thursday, November 16, 2023
Other Manufacturing, Hardware, Engineering, Chemicals, Plastics, Technology, Aerospace, Manufacturing, Other Technology, Sale, EBITDA, Interest, Research, Policy, Keur Simbara, Capital expenditure, Depreciation, Investment, OPEX, Samsung Galaxy Note 7, United, Capital, Printing, BofA Securities, EUR, Conference, EIB, Adjustment, European Investment Bank, Communication, Operating cost, Forecasting, 3D, System, Government, 3D printing, Retail, Clothing, Video game, Music, Pharmaceutical industry, Bank, Security (finance), Reinsurance, Film industry, Fine chemical, Cryptocurrency, Voxeljet, Anzu

Systems revenues represented 54.9% of total revenues in the third quarter of 2023 compared to 47.1% in last year’s third quarter.

Key Points: 
  • Systems revenues represented 54.9% of total revenues in the third quarter of 2023 compared to 47.1% in last year’s third quarter.
  • Cost of sales were kEUR 4,515 for the third quarter of 2023 compared to kEUR 4,089 for the third quarter of 2022.
  • Selling expenses were kEUR 1,790 for the third quarter of 2023 compared to kEUR 2,015 in the third quarter of 2022.
  • Administrative expenses were kEUR 1,782 for the third quarter of 2023 compared to kEUR 1,566 in the third quarter of 2022.

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Retrieved on: 
Monday, November 20, 2023
Classification, China Biologic Products, Special-purpose acquisition company, CDMO, Bank statement, USD, American depositary receipt, BofA Securities, Infection, Documentation, GAAP, EIB, European Investment Bank, NPV, I&I, Letter, Autoimmunity, WACC, Cryptocurrency

JERUSALEM, Nov. 20, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced today the receipt of formal notification from the Nasdaq Stock Market ("Nasdaq") that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders' equity.

Key Points: 
  • JERUSALEM, Nov. 20, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced today the receipt of formal notification from the Nasdaq Stock Market ("Nasdaq") that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders' equity.
  • Nasdaq indicated that their determination that the Company complies with Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum $2.5 million in stockholders' equity, is based on the content of the Company's Form 6-K dated November 13, 2023.
  • This change impacted the classification of most of the current and future warrants as equity and not as liabilities, as per GAAP accounting rules.
  • The Company expects this new WACC to be incorporated in the Company's financial statements for the year ending December 31, 2023.

Ørsted partners with Breakthrough Energy Catalyst, the European Commission, and the European Investment Bank for FlagshipONE

Retrieved on: 
Thursday, December 14, 2023
Energi, Climate, Carbon, Government, European Investment Bank, Private sector, Renewable energy, InvestEU, EIB, Civil service commission, BofA Securities, European Commission, Breakthrough Energy, Water, COP28, Partnership, Electricity, Oil

Ørsted partners with Breakthrough Energy Catalyst, the European Commission, and the European Investment Bank for FlagshipONE

Key Points: 
  • Ørsted partners with Breakthrough Energy Catalyst, the European Commission, and the European Investment Bank for FlagshipONE
    Today, at COP28, Ørsted announced that the EU-Catalyst Partnership, which consists of the European Commission, Breakthrough Energy Catalyst, and the European Investment Bank, has vowed to support Ørsted’s FlagshipONE project, highlighting the innovative nature of this project and its potential to contribute to the decarbonisation of shipping.
  • FlagshipONE is Europe’s largest e-methanol plant and is currently the world’s strongest proof point that carbon-neutral shipping is possible.
  • Breakthrough Energy Catalyst is a first-of-its-kind model, bringing together government partners and leading organisations from across the private sector to fund and scale emerging climate technologies.
  • Breakthrough Energy Catalyst will acquire a 15 % equity interest in FlagshipONE and provide a grant to the project, subject to the fulfilment of funding conditions.

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

Retrieved on: 
Friday, November 3, 2023
European Investment Bank, IBN, BofA Securities, Infection, I&I, Autoimmunity, EIB, Calendar, China Biologic Products, Letter, Auction

JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.

Key Points: 
  • JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.
  • In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days to regain compliance.
  • Scinai intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement.
  • As a result of the potential extension, the Company expects a positive impact on Scinai’s shareholders’ equity, which could enable the Company to restore compliance with Nasdaq Listing Rules regarding minimum shareholders’ equity, subject to the discretion of Nasdaq.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
Wednesday, November 1, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, PIK, Code, Partnership, Nanobiotix, EIB, State Street, Tax, Guggenheim Partners, EDGAR, Jefferies Group, Telephone, Form, 3rd Floor, Cancer, Patient, Security (finance), Park Avenue, The 8th Floor, Research, Floor, Application, NANO, ADS, Madison Avenue, Note, AMF, European Investment Bank, Documentation, Milestone, NBTXR3, ISIN, Private, Attention, BofA Securities, Risk, Prospectus, Commercial code, Pharmaceutical industry, Bank, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
Wednesday, November 1, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, PIK, Code, Partnership, Nanobiotix, EIB, State Street, Tax, Guggenheim Partners, EDGAR, Jefferies Group, Telephone, Form, 3rd Floor, Cancer, Patient, Security (finance), Park Avenue, The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, European Investment Bank, Documentation, Milestone, NBTXR3, ISIN, Private, Attention, BofA Securities, Prospectus, Commercial code, Pharmaceutical industry, Bank, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, October 31, 2023
European Investment Bank, Max Planck, Psoriasis, IBN, University Medical Center, AMD, CDMO, BofA Securities, COVID-19, Marketing, Partnership, Asthma, Animal, Infection, I&I, Autoimmunity, Table, EIB, China Biologic Products, Pharmaceutical industry, Clothing, Rare-earth element

R&D expenses for the three months ended Sept. 30, 2023 amounted to $1.13 million compared to $1.19 million for the three months ended Sept. 30, 2022.

Key Points: 
  • R&D expenses for the three months ended Sept. 30, 2023 amounted to $1.13 million compared to $1.19 million for the three months ended Sept. 30, 2022.
  • Total operating expenses for the three months ended Sept. 30, 2023 amounted to $2.1 million compared to $2.1 million for the three months ended Sept. 30, 2022.
  • Financial income for the three months ended Sept. 30, 2023 amounted to $5.2 million compared to $6.9 million income for the three months ended Sept. 30, 2022.
  • As of Sept. 30, 2023, Scinai had cash and cash equivalents of $6.4 million as compared to $14.2 million as of Dec. 31, 2022.

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot

Retrieved on: 
Tuesday, October 31, 2023
European Investment Bank, IBN, BofA Securities, Infection, I&I, Autoimmunity, EIB, European, Patient, China Biologic Products, Bank

Formal feedback from the EIB management regarding a definitive amendment to the facility is anticipated as soon as November 2023.

Key Points: 
  • Formal feedback from the EIB management regarding a definitive amendment to the facility is anticipated as soon as November 2023.
  • Currently, the EIB is considering extending a maturity of EIB’s venture debt facility to Scinai in light of the Company’s recent strategic shift.
  • In September 2023, as part of the Company’s strategic pivot, the Company rebranded as Scinai Immunotherapeutics.
  • There is no guarantee that the EIB will approve the adjustment of the terms of the EIB’s financial facility with the Company, including the delay of the facility’s maturity.

EQS-News: PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights

Retrieved on: 
Thursday, October 26, 2023
Frankfurt Stock Exchange, European Investment Bank, Patent, ISIN, Financial Oversight and Management Board for Puerto Rico, BofA Securities, Supervisory board, Nice, Partnership, EUR, Federal Gazette, CFO, Investment, Remimazolam, Anesthesia, Security (finance)

For further details on the capital increase with subscription rights, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 23 October 2023 and on the website of PAION AG ( www.paion.com ).

Key Points: 
  • For further details on the capital increase with subscription rights, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 23 October 2023 and on the website of PAION AG ( www.paion.com ).
  • PAION will receive gross proceeds of about EUR 9 million for the capital increase with subscription rights.
  • Tilmann Bur, CEO of PAION AG, commented: "This capital increase is an important step towards achieving our growth targets.
  • Sebastian Werner, CFO of PAION AG, added: ”This capital increase marks a first important milestone in our overarching financing strategy.

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Retrieved on: 
Monday, October 23, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, European Investment Bank, A-T, FDA, Ageing, Therapy, Neurodegenerative disease, Acquisition, DSP, AIDE, Disease, Clinical trial, Biology, NDA, Safety, SPA, Patient, EIB, Pharmaceutical industry, Quince

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company.

Key Points: 
  • Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company.
  • Currently, there are no approved treatments for A-T and the market represents a $1+ billion estimated peak sales opportunity globally.
  • “The successful closing of the EryDel acquisition is an exciting step forward in fulfilling our vision to build a leading rare disease biotechnology company,” said Dirk Thye, M.D., Quince’s Chief Executive Officer.
  • The acquisition of EryDel was completed with no upfront cash payment, using a stock-for-stock exchange and potential downstream milestone cash payments.